H. Lokhorst

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
H M Lokhorst, H.m Lokhorst, H Lokhorst, H. M. Lokhorst, H. Lokhorst, H.m. Lokhorst, Henk M Lokhorst, Henk Lokhorst, Henk M. Lokhorst
Publication record
386 papers · 24,433 citations · H-index 80

PAPERS

Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial
20242 citationsauthor #3
Detection and localization of early- and late-stage cancers using platelet RNA.
202291 citationsauthor #65
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
202125 citationsauthor #20
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
20210 citationsauthor #20
Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma
202014 citationsauthor #11
Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
201927 citationsauthor #12
Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials
20191 citationsauthor #18
Syddansk Universitet High-Parameter Mass Cytometry Evaluation of Relapsed / Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
20190 citationsauthor #15
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma
201922 citationsauthor #7
University of Southern Denmark High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
20190 citationsauthor #15
The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma
201914 citationsauthor #7
Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up
20193 citationsauthor #2
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells
2019151 citationsauthor #9
Immunotherapy in myeloma: how far have we come?
201958 citationsauthor #3
T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells
20197 citationsauthor #8
Association between low-grade inflammation and Breast cancer and B-cell Myeloma and Non-Hodgkin Lymphoma: findings from two prospective cohorts
201813 citationsauthor #29
Pre‐diagnostic blood immune markers, incidence and progression of B‐cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses
201817 citationsauthor #7
Discovery, Development, and Mechanisms of Action of the Human CD38 Antibody Daratumumab
20183 citationsauthor #7
Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal
20180 citationsauthor #13
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
2018185 citationsauthor #3
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
2018142 citationsauthor #15
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
201864 citationsauthor #6
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
201855 citationsauthor #19
Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies
201847 citationsauthor #8
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
201830 citationsauthor #21
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
201821 citationsauthor #21
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
201832 citationsauthor #14
A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma
201726 citationsauthor #19
A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma
201726 citationsauthor #20
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma
201726 citationsauthor #5
Treatment options for relapse after autograft in multiple myeloma – report from an EBMT educational meeting
20178 citationsauthor #5
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
2017123 citationsauthor #4
Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius
201712 citationsauthor #6
A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials
20170 citationsauthor #6
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
201765 citationsauthor #5
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
2017144 citationsauthor #16
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
2017240 citationsauthor #11
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study
201714 citationsauthor #16
The Combination of 41BB and CD28 Costimulatory Signals Endows Lower Affinity CAR T Cells with the Most Optimal Properties for Selective Targeting of the Tumor Associated Antigen CD38
20170 citationsauthor #5
Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
201731 citationsauthor #4
Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial
20177 citationsauthor #12
Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients
201727 citationsauthor #12
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.
2017200 citationsauthor #12
Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding
20175 citationsauthor #5
Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
20161 citationsauthor #4
Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)
201630 citationsauthor #4
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
2016109 citationsauthor #20
Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial
201613 citationsauthor #13
PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
201612 citationsauthor #12
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
2016188 citationsauthor #11
Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses
201634 citationsauthor #6
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
2016343 citationsauthor #16
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
201674 citationsauthor #3
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
2016313 citationsauthor #7
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
201618 citationsauthor #5
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma
20168 citationsauthor #14
High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action
20169 citationsauthor #16
Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives
201629 citationsauthor #3
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
2016313 citationsauthor #17
Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
201641 citationsauthor #13
Clinical ef fi cacy and management of monoclonal antibodies targeting CD 38 and SLAMF 7 in multiple myeloma
201614 citationsauthor #11
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
201639 citationsauthor #4
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
2016343 citationsauthor #17
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
201654 citationsauthor #22
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016)
20160 citationsauthor #4
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
2016846 citationsauthor #13
Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long‐term follow‐up in a single institution
201620 citationsauthor #7
Reducing on-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors By Affinity Optimization
201611 citationsauthor #5
Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
201654 citationsauthor #4
Abstract A12: Combination of the anti-CD38 monoclonal antibody daratumumab and all-trans retinoic acid.
20150 citationsauthor #2
Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study.
2015114 citationsauthor #28
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
2015242 citationsauthor #6
Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial
201536 citationsauthor #27
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
20151,809 citationsauthor #4
Abstract PR12: Biological insights into tumor-bone marrow microenvironment interactions derived from a humanized murine model
20151 citationsauthor #14
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
2015242 citationsauthor #5
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitor (PI) and Immunomodulatory Drug (IMiD) Treatment
20153 citationsauthor #4
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.
2015102 citationsauthor #13
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip
201574 citationsauthor #8
Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy
20152 citationsauthor #7
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
2015103 citationsauthor #6
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
201546 citationsauthor #17
Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
201513 citationsauthor #10
Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis
201524 citationsauthor #5
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
2015151 citationsauthor #13
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
20151,009 citationsauthor #1
Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology
201520 citationsauthor #15
Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients
20151 citationsauthor #18
Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement.
20159 citationsauthor #7
Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective
20152 citationsauthor #5
Exposure-Response Relationship of Daratumumab Efficacy and Safety in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs)
20150 citationsauthor #5
Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival
201512 citationsauthor #1
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
2015389 citationsauthor #7
Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma
201510 citationsauthor #11
Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations
20150 citationsauthor #6
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
201561 citationsauthor #12
The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs
201519 citationsauthor #8
Revised-international staging system (R-ISS): A new and simple prognostic assessment for multiple myeloma
20141 citationsauthor #13
Identification of minor histocompatibility antigens based on the 1000 Genomes Project
201430 citationsauthor #2
Potential prognostic implications of whole‐body bone marrow MRI in diffuse large B‐cell lymphoma patients with a negative blind bone marrow biopsy
201417 citationsauthor #3

TIMELINE

1975 6 citations

1983 7 citations

1986 35 citations

1987 33 citations

1988 26 citations

1989 72 citations

1990 10 citations

1992 273 citations

1993 25 citations

1994 372 citations

1996 377 citations

1997 544 citations

1998 175 citations

1999 241 citations

2000 365 citations

2001 213 citations

2002 183 citations

2003 794 citations

2004 769 citations

2005 224 citations

2006 383 citations

2007 250 citations

2008 1,104 citations

2009 727 citations

2010 1,501 citations

2011 2,178 citations

2012 2,300 citations

2013 697 citations

2014 1,139 citations

2015 4,252 citations

2016 2,573 citations

2017 928 citations

2018 609 citations

2019 283 citations

2020 14 citations

2021 25 citations

2022 91 citations

2024 2 citations

H. Lokhorst

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT